

PharmaEssentia

PharmaEssentia Defines a Growth-Oriented Discovery and Development Strategy with Newly Appointed CSO Dr. Lih-Ling Lin at the Helm

PharmaEssentia is building on nearly two decades of invention and discovery-based innovation; now it looks to the future with a renewed focus on category-defining breakthroughs



October 1, 2022 – PharmaEssentia Corporation (PEC) is building a differentiated profile among pharmaceutical innovators, with headquarters in Taiwan, dedicated manufacturing facilities, and a marketed product that was invented by the company’s founders and is approved in several countries around the world. For years, the company’s R&D leaders have focused on optimizing interferon using a proprietary pegylation technology to overcome the limitations of conventional interferons and broaden its applicability to patients who can benefit from the power of this technology to control disease mechanisms.

As part of these efforts, PEC has continued to make steady progress on a diverse pipeline that aims to expand the current product indication into related disease areas where this technology may effectively address unmet needs. Now, with numerous programs in later stages of development and collaborations with some of the world’s most renowned experts, the company has begun to appreciate the vast opportunities it has to expand its expertise and accelerate discovery efforts across the related therapeutic fields of hematology, oncology and immunology.

The company recently appointed renowned immunologist Lih-Ling Lin, Ph.D., formerly a leader in immunology and inflammation at Sanofi, as Chief Scientific Officer to lead this important discovery work.

Dr. Lin describes her focus:

“We see tremendous opportunities to apply our core expertise to logical adjacencies that connect hematology and oncology biology to inflammation and other immunological mechanisms. From my perspective, we are uniquely positioned to lead these efforts, bringing forward exciting early discoveries in immunology to develop highly targeted novel therapeutics in multiple disease areas. Already we are initiating experiments to validate our platform and are attracting new talent with immunology expertise who will be critical to accelerating these efforts.”

Following an initial listening and discovery tour of the R&D network across PEC, Dr. Lin has worked together with her leadership to define a clear roadmap toward discovery efforts across these therapeutic area pillars. Part of the company’s efforts will be to extend the R&D network into the Boston metropolitan area, aligned with the company’s growing footprint in the United States. Dr. Lin is leveraging her extensive network to recruit an expanded team trained to leverage state-of-the-art technologies, data sciences and machine learning discovery tools. This team will focus on protein engineering, antibody discovery and new modality development that will support the identification and development of novel therapeutic candidates.

PharmaEssentia

Ko-Chung Lin, Ph.D., Founder and Chief Executive Officer, adds his view on the impact of early R&D to the company strategy:

“Taking the lessons from our efforts to date, we are confident that there is much more we can do to build our leadership in discovery efforts that will uncover therapeutic opportunities and bridge connections between the hem/onc and immunology fields. And we are thrilled to have Dr. Lin’s expertise and passion to lead these efforts and accelerate our progress. We see this as a formative element of the company’s growth strategy over time, as we expand our MPN leadership toward new areas where we can showcase our unique combination of scientific knowledge, innovation excellence and passion for patient care.”

With this clear focus, Dr. Lin and team expect to begin high-impact initiatives and collaborations to bring their discovery efforts into the forefront of scientific dialogue and strengthen and diversify the company’s full pipeline in the coming years. With PEC’s track record of innovation and Dr. Lin’s vision, the company is poised for a dramatic transformation into a robust, global R&D engine for transformative patient care.

Forward-Looking Statement

This article may contain forward-looking statements, including statements regarding our pipeline and research and development efforts. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and similar legislation and regulations under Taiwanese law. These forward-looking statements are based on management expectations and assumptions as of the posting of this article, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, and regulatory submissions. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.